Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: A prospective randomized study

Jiann-Loung Hwang, Kok Min Seow, Yu Hung Lin, Lee Wen Huang, Bih Chwen Hsieh, Yieh Loong Tsai, Gong Jhe Wu, Shih Chia Huang, Chin Yu Chen, Pien Hsin Chen, Chii Ruey Tzeng

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Patients with polycystic ovary syndrome (PCOS) may need a longer period of pituitary downregulation to suppress the elevated serum LH and androgen levels effectively during IVF treatment using the GnRH agonist long protocol. We proposed a stimulation protocol incorporating Diane-35 and GnRH antagonist (Diane/cetrorelix protocol) and compared it with the GnRH agonist long protocol for PCOS patients. Methods: Part I of the study was an observational pilot study to evaluate the hormonal change as a result of the Diane/cetrorelix protocol (n = 26). Part II of the study was a prospective randomized study comparing the Diane/cetrorelix protocol (n = 25) and the GnRH agonist long protocol (n = 24). In the Diane/cetrorelix protocol, patients were pretreated with three cycles of Diane-35, followed by 0.25 mg of cetrorelix on cycle day 3. From day 4, cetrorelix and gonadotrophin were administered concomitantly until the day of HCG injection. Results: Serum LH, estradiol and testosterone levels were suppressed comparably in both protocols at the start of gonadotrophin administration. Serum LH was suppressed at constant levels without a premature LH surge in the Diane/cetrorelix protocol. The clinical results for both protocols were comparable, with significantly fewer days of injection, lower amounts of gonadotrophin used and lower estradiol levels on the day of HCG injection following the Diane/cetrorelix protocol. Furthermore, there was no significant difference in clinical pregnancy outcome between the two stimulation protocols. Conclusions: The Diane/cetrorelix protocol has a similar pregnancy outcome to the GnRH agonist long protocol for women with PCOS undergoing IVF treatment.

Original languageEnglish
Pages (from-to)1993-2000
Number of pages8
JournalHuman Reproduction
Volume19
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Ovulation Induction
Polycystic Ovary Syndrome
Prospective Studies
Gonadotropin-Releasing Hormone
Gonadotropins
Therapeutics
Pregnancy Outcome
Injections
Estradiol
Serum
Ethinyl estradiol drug combination Cyproterone acetate
cetrorelix
Androgens
Observational Studies
Testosterone
Down-Regulation

Keywords

  • Cetrorelix acetate
  • Diane-35
  • GnRH antagonist
  • HMG
  • PCOS

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome : A prospective randomized study. / Hwang, Jiann-Loung; Seow, Kok Min; Lin, Yu Hung; Huang, Lee Wen; Hsieh, Bih Chwen; Tsai, Yieh Loong; Wu, Gong Jhe; Huang, Shih Chia; Chen, Chin Yu; Chen, Pien Hsin; Tzeng, Chii Ruey.

In: Human Reproduction, Vol. 19, No. 9, 09.2004, p. 1993-2000.

Research output: Contribution to journalArticle

Hwang, Jiann-Loung ; Seow, Kok Min ; Lin, Yu Hung ; Huang, Lee Wen ; Hsieh, Bih Chwen ; Tsai, Yieh Loong ; Wu, Gong Jhe ; Huang, Shih Chia ; Chen, Chin Yu ; Chen, Pien Hsin ; Tzeng, Chii Ruey. / Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome : A prospective randomized study. In: Human Reproduction. 2004 ; Vol. 19, No. 9. pp. 1993-2000.
@article{f52ada3da3684d9abab276e9527ec5be,
title = "Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: A prospective randomized study",
abstract = "Background: Patients with polycystic ovary syndrome (PCOS) may need a longer period of pituitary downregulation to suppress the elevated serum LH and androgen levels effectively during IVF treatment using the GnRH agonist long protocol. We proposed a stimulation protocol incorporating Diane-35 and GnRH antagonist (Diane/cetrorelix protocol) and compared it with the GnRH agonist long protocol for PCOS patients. Methods: Part I of the study was an observational pilot study to evaluate the hormonal change as a result of the Diane/cetrorelix protocol (n = 26). Part II of the study was a prospective randomized study comparing the Diane/cetrorelix protocol (n = 25) and the GnRH agonist long protocol (n = 24). In the Diane/cetrorelix protocol, patients were pretreated with three cycles of Diane-35, followed by 0.25 mg of cetrorelix on cycle day 3. From day 4, cetrorelix and gonadotrophin were administered concomitantly until the day of HCG injection. Results: Serum LH, estradiol and testosterone levels were suppressed comparably in both protocols at the start of gonadotrophin administration. Serum LH was suppressed at constant levels without a premature LH surge in the Diane/cetrorelix protocol. The clinical results for both protocols were comparable, with significantly fewer days of injection, lower amounts of gonadotrophin used and lower estradiol levels on the day of HCG injection following the Diane/cetrorelix protocol. Furthermore, there was no significant difference in clinical pregnancy outcome between the two stimulation protocols. Conclusions: The Diane/cetrorelix protocol has a similar pregnancy outcome to the GnRH agonist long protocol for women with PCOS undergoing IVF treatment.",
keywords = "Cetrorelix acetate, Diane-35, GnRH antagonist, HMG, PCOS",
author = "Jiann-Loung Hwang and Seow, {Kok Min} and Lin, {Yu Hung} and Huang, {Lee Wen} and Hsieh, {Bih Chwen} and Tsai, {Yieh Loong} and Wu, {Gong Jhe} and Huang, {Shih Chia} and Chen, {Chin Yu} and Chen, {Pien Hsin} and Tzeng, {Chii Ruey}",
year = "2004",
month = "9",
doi = "10.1093/humrep/deh375",
language = "English",
volume = "19",
pages = "1993--2000",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome

T2 - A prospective randomized study

AU - Hwang, Jiann-Loung

AU - Seow, Kok Min

AU - Lin, Yu Hung

AU - Huang, Lee Wen

AU - Hsieh, Bih Chwen

AU - Tsai, Yieh Loong

AU - Wu, Gong Jhe

AU - Huang, Shih Chia

AU - Chen, Chin Yu

AU - Chen, Pien Hsin

AU - Tzeng, Chii Ruey

PY - 2004/9

Y1 - 2004/9

N2 - Background: Patients with polycystic ovary syndrome (PCOS) may need a longer period of pituitary downregulation to suppress the elevated serum LH and androgen levels effectively during IVF treatment using the GnRH agonist long protocol. We proposed a stimulation protocol incorporating Diane-35 and GnRH antagonist (Diane/cetrorelix protocol) and compared it with the GnRH agonist long protocol for PCOS patients. Methods: Part I of the study was an observational pilot study to evaluate the hormonal change as a result of the Diane/cetrorelix protocol (n = 26). Part II of the study was a prospective randomized study comparing the Diane/cetrorelix protocol (n = 25) and the GnRH agonist long protocol (n = 24). In the Diane/cetrorelix protocol, patients were pretreated with three cycles of Diane-35, followed by 0.25 mg of cetrorelix on cycle day 3. From day 4, cetrorelix and gonadotrophin were administered concomitantly until the day of HCG injection. Results: Serum LH, estradiol and testosterone levels were suppressed comparably in both protocols at the start of gonadotrophin administration. Serum LH was suppressed at constant levels without a premature LH surge in the Diane/cetrorelix protocol. The clinical results for both protocols were comparable, with significantly fewer days of injection, lower amounts of gonadotrophin used and lower estradiol levels on the day of HCG injection following the Diane/cetrorelix protocol. Furthermore, there was no significant difference in clinical pregnancy outcome between the two stimulation protocols. Conclusions: The Diane/cetrorelix protocol has a similar pregnancy outcome to the GnRH agonist long protocol for women with PCOS undergoing IVF treatment.

AB - Background: Patients with polycystic ovary syndrome (PCOS) may need a longer period of pituitary downregulation to suppress the elevated serum LH and androgen levels effectively during IVF treatment using the GnRH agonist long protocol. We proposed a stimulation protocol incorporating Diane-35 and GnRH antagonist (Diane/cetrorelix protocol) and compared it with the GnRH agonist long protocol for PCOS patients. Methods: Part I of the study was an observational pilot study to evaluate the hormonal change as a result of the Diane/cetrorelix protocol (n = 26). Part II of the study was a prospective randomized study comparing the Diane/cetrorelix protocol (n = 25) and the GnRH agonist long protocol (n = 24). In the Diane/cetrorelix protocol, patients were pretreated with three cycles of Diane-35, followed by 0.25 mg of cetrorelix on cycle day 3. From day 4, cetrorelix and gonadotrophin were administered concomitantly until the day of HCG injection. Results: Serum LH, estradiol and testosterone levels were suppressed comparably in both protocols at the start of gonadotrophin administration. Serum LH was suppressed at constant levels without a premature LH surge in the Diane/cetrorelix protocol. The clinical results for both protocols were comparable, with significantly fewer days of injection, lower amounts of gonadotrophin used and lower estradiol levels on the day of HCG injection following the Diane/cetrorelix protocol. Furthermore, there was no significant difference in clinical pregnancy outcome between the two stimulation protocols. Conclusions: The Diane/cetrorelix protocol has a similar pregnancy outcome to the GnRH agonist long protocol for women with PCOS undergoing IVF treatment.

KW - Cetrorelix acetate

KW - Diane-35

KW - GnRH antagonist

KW - HMG

KW - PCOS

UR - http://www.scopus.com/inward/record.url?scp=4544323556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544323556&partnerID=8YFLogxK

U2 - 10.1093/humrep/deh375

DO - 10.1093/humrep/deh375

M3 - Article

C2 - 15284212

AN - SCOPUS:4544323556

VL - 19

SP - 1993

EP - 2000

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 9

ER -